Safety and Tolerability of ADR-001 Therapy for Immunoglobulin A Nephropathy.

Akihito Tanaka Kazuhiro Furuhashi Kumiko FujiedaAsuka HorinouchiKayaho MaedaShoji SaitoTetsushi MimuraYosuke SakaTomohiko NaruseTakuji Ishimoto Noritoshi KatoTomoki KosugiFumie KinoshitaYachiyo KuwatsukaYasuhiro NakaiShoichi Maruyama

Published in: Kidney360 (2024)

This trial was registered with the Japan Registry of Clinical Trials (jRCT2043200002; registration date: April 14, 2020) and ClinicalTrials.gov (NCT04342325; registration date: April 13, 2020).

Keyphrases

clinical trial
open label
phase ii
phase iii
double blind
study protocol
placebo controlled
adverse drug
randomized controlled trial
emergency department
electronic health record
drug induced